Korean Diabetes J.  2010 Apr;34(2):84-85. 10.4093/kdj.2010.34.2.84.

Serum Cystatin C as a Biomarker for Predicting Coronary Artery Disease in Diabetes

• Oh JY

• KMID: 2222381
• DOI: http://doi.org/10.4093/kdj.2010.34.2.84

Abstract

No abstract available.

MeSH Terms

Coronary Artery Disease
Coronary Vessels
Cystatin C
Cystatin C

Reference

1. American Diabetes Association. Standards of medical care in diabetes: 2010. Diabetes Care. 2010. 33:Suppl 1. S11–S61.

2. Folsom AR, Chambless LE, Duncan BB, Gilbert AC, Pankow JS. Prediction of coronary heart disease in middle-aged adults with diabetes. Diabetes Care. 2003. 26:2777–2784.

3. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999. 340:115–126.

4. Cohn JN, Quyyumi AA, Hollenberg NK, Jamerson KA. Surrogate markers for cardiovascular disease: functional markers. Circulation. 2004. 109:IV31–IV46.

5. Mancini GB, Dahlof B, Diez J. Surrogate markers for cardiovascular disease: structural markers. Circulation. 2004. 109:IV22–IV30.

6. Ikonomidis I, Stamatelopoulos K, Lekakis J, Vamvakou GD, Kremastinos DT. Inflammatory and non-invasive vascular markers: the multimarker approach for risk stratification in coronary artery disease. Atherosclerosis. 2008. 199:3–11.

7. Sattar N, Wannamethee G, Sarwar N, Chernova J, Lawlor DA, Kelly A, Wallace AM, Danesh J, Whincup PH. Leptin and coronary heart disease: prospective study and systematic review. J Am Coll Cardiol. 2009. 53:167–175.

8. Antoniades C, Antonopoulos AS, Tousoulis D, Stefanadis C. Adiponectin: from obesity to cardiovascular disease. Obes Rev. 2009. 10:269–279.

9. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005. 111:932–939.

10. von Eynatten M, Lepper PM, Liu D, Lang K, Baumann M, Nawroth PP, Bierhaus A, Dugi KA, Heemann U, Allolio B, Humpert PM. Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease. Diabetologia. 2007. 50:1930–1937.

11. Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis. 2001. 37:79–83.

12. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005. 352:2049–2060.

13. Sarnak MJ, Katz R, Stehman-Breen CO, Fried LF, Jenny NS, Psaty BM, Newman AB, Siscovick D, Shlipak MG. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med. 2005. 142:497–505.

14. Parikh NI, Hwang SJ, Yang Q, Larson MG, Guo CY, Robins SJ, Sutherland P, Benjamin EJ, Levy D, Fox CS. Clinical correlates and heritability of cystatin C (from the Framingham Offspring Study). Am J Cardiol. 2008. 102:1194–1198.

15. Muntner P, Mann D, Winston J, Bansilal S, Farkouh ME. Serum cystatin C and increased coronary heart disease prevalence in US adults without chronic kidney disease. Am J Cardiol. 2008. 102:54–57.

16. Shlipak MG, Simon JA, Grady D, Lin F, Wenger NK, Furberg CD. Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J Am Coll Cardiol. 2001. 38:705–711.

17. Ix JH, de Boer IH, Wassel CL, Criqui MH, Shlipak MG, Whooley MA. Urinary creatinine excretion rate and mortality in persons with coronary artery disease: the Heart and Soul Study. Circulation. 2010. 121:1295–1303.

18. Beilby J, Divitini ML, Knuiman MW, Rossi E, Hung J. Comparison of cystatin C and creatinine as predictors of cardiovascular events in a community-based elderly population. Clin Chem. Forthcoming 2010.

19. Kim EH, Yu JH, Lee SA, Kim EY, Kim WG, Lee SH, Cho EH, Koh EH, Lee WJ, Kim MS, Park JY, Lee KU. Lack of association between serum cystatin C levels and coronary artery disease in diabetic patients. Korean Diabetes J. 2010. 34:95–100.